117 related articles for article (PubMed ID: 11453736)
21. Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite.
Randerath K; Moorthy B; Mabon N; Sriram P
Carcinogenesis; 1994 Oct; 15(10):2087-94. PubMed ID: 7955037
[TBL] [Abstract][Full Text] [Related]
22. Minor products of reaction of DNA with alpha-acetoxytamoxifen.
Osborne MR; Hardcastle IR; Phillips DH
Carcinogenesis; 1997 Mar; 18(3):539-43. PubMed ID: 9067554
[TBL] [Abstract][Full Text] [Related]
23. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
24. Effect of N,N-didesmethyltamoxifen upon DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen.
Gamboa da Costa G; Marques MM; Fu X; Churchwell MI; Wang YP; Doerge DR; Beland FA
Cancer Lett; 2007 Nov; 257(2):191-8. PubMed ID: 17765393
[TBL] [Abstract][Full Text] [Related]
25. Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture.
Glatt H; Davis W; Meinl W; Hermersdörfer H; Venitt S; Phillips DH
Carcinogenesis; 1998 Oct; 19(10):1709-13. PubMed ID: 9806149
[TBL] [Abstract][Full Text] [Related]
26. Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen.
Pathak DN; Pongracz K; Bodell WJ
Carcinogenesis; 1996 Sep; 17(9):1785-90. PubMed ID: 8824496
[TBL] [Abstract][Full Text] [Related]
27. Sex differences in the activation of tamoxifen to DNA binding species in rat liver in vivo and in rat hepatocytes in vitro: role of sulfotransferase induction.
Davis W; Hewer A; Rajkowski KM; Meinl W; Glatt H; Phillips DH
Cancer Res; 2000 Jun; 60(11):2887-91. PubMed ID: 10850433
[TBL] [Abstract][Full Text] [Related]
28. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.
Murphy CS; Langan-Fahey SM; McCague R; Jordan VC
Mol Pharmacol; 1990 Nov; 38(5):737-43. PubMed ID: 2233701
[TBL] [Abstract][Full Text] [Related]
29. Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture.
Sharma M; Shubert DE; Sharma M; Rodabaugh KJ; McGarrigle BP; Vezina CM; Bofinger DP; Olson JR
Biochem Biophys Res Commun; 2003 Jul; 307(1):157-64. PubMed ID: 12849995
[TBL] [Abstract][Full Text] [Related]
30. DNA adducts formed from 4-hydroxytamoxifen are more mutagenic than those formed by alpha-acetoxytamoxifen in a shuttle vector target gene replicated in human Ad293 cells.
McLuckie KI; Routledge MN; Brown K; Gaskell M; Farmer PB; Roberts GC; Martin EA
Biochemistry; 2002 Jul; 41(28):8899-906. PubMed ID: 12102632
[TBL] [Abstract][Full Text] [Related]
31. Alpha-hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro.
Boocock DJ; Maggs JL; White IN; Park BK
Carcinogenesis; 1999 Jan; 20(1):153-60. PubMed ID: 9934863
[TBL] [Abstract][Full Text] [Related]
32. Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen.
McCague R; Parr IB; Leclercq G; Leung OT; Jarman M
Biochem Pharmacol; 1990 May; 39(9):1459-65. PubMed ID: 2334445
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and sulfatase inhibitory activities of (E)- and (Z)-4-hydroxytamoxifen sulfamates.
Chu GH; Peters A; Selcer KW; Li PK
Bioorg Med Chem Lett; 1999 Jan; 9(2):141-4. PubMed ID: 10021916
[TBL] [Abstract][Full Text] [Related]
34. Short-term dosing of alpha-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats.
White IN; Carthew P; Davies R; Styles J; Brown K; Brown JE; Smith LL; Martin EA
Carcinogenesis; 2001 Apr; 22(4):553-7. PubMed ID: 11285188
[TBL] [Abstract][Full Text] [Related]
35. Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of alpha-hydroxytamoxifen in rat and human livers.
Kim SY; Laxmi YR; Suzuki N; Ogura K; Watabe T; Duffel MW; Shibutani S
Drug Metab Dispos; 2005 Nov; 33(11):1673-8. PubMed ID: 16099924
[TBL] [Abstract][Full Text] [Related]
36. Species differences in the metabolic activation of tamoxifen into genotoxic derivatives: risk assessment in women.
De Matteis F; White IN; Smith LL
Eur J Drug Metab Pharmacokinet; 1998; 23(3):425-8. PubMed ID: 9842987
[TBL] [Abstract][Full Text] [Related]
37. Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen.
Pongracz K; Pathak DN; Nakamura T; Burlingame AL; Bodell WJ
Cancer Res; 1995 Jul; 55(14):3012-5. PubMed ID: 7606720
[TBL] [Abstract][Full Text] [Related]
38. Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts.
Shibutani S; Shaw PM; Suzuki N; Dasaradhi L; Duffel MW; Terashima I
Carcinogenesis; 1998 Nov; 19(11):2007-11. PubMed ID: 9855017
[TBL] [Abstract][Full Text] [Related]
39. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen.
Shibutani S; Ravindernath A; Suzuki N; Terashima I; Sugarman SM; Grollman AP; Pearl ML
Carcinogenesis; 2000 Aug; 21(8):1461-7. PubMed ID: 10910945
[TBL] [Abstract][Full Text] [Related]
40. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
